Ferdane Ataş

Ferdane Ataş

Auto-generated profile, based on publicly available information

Ferdane Ataş

Department of Ophthalmology, Çerkezköy State Hospital, Tekirdağ, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
FAFerdane Atas
Ferdane Atas
MKMahmut Kaya
Mahmut Kaya
ASAli Osman Saatci
Ali Osman Saatci
To report a case with acute posterior multifocal placoid pigment epitheliopathy (APMPPE)-like presentation following the first dose of BNT162b2 COVID-19 vaccinationAn otherwise healthy 45-year-old ...

15 March 2023 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
CDCemal Demirlek
Cemal Demirlek
FAFerdane Atas
Ferdane Atas
BYBerna Yalincetin
Berna Yalincetin
MGMerve S. Gurbuz
Merve S. Gurbuz
ECEzgi Cesim
Ezgi Cesim
EBEmre Bora
Emre Bora

1 January 2021 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
MKMahmut Kaya
Mahmut Kaya
FÖFerit Hakan Öner
Ferit Hakan Öner
BYBetül Akbulut Yağcı
Betül Akbulut Yağcı
FAFerdane Ataş
Ferdane Ataş
TOTaylan Ozturk
Taylan Ozturk
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of neovascular age-related macular degeneration (nAMD). The medical records of patients receiving anti-VEGF treatment for nAMD between January 2015 and March 2019 were retrospectively analyzed. Preoperative and postoperative routine ophthalmological examinations, central macular thickness, duration of inflammation, and follow-up time of the patients with non-infectious IOI following anti-VEGF injection were recorded. Non-infectious IOI was determined in 13 eyes (11 eyes with aflibercept, 2 eyes with ranibizumab) of 1,966 patients who received a total of 12,652 anti-VEGF (4,796 aflibercept and 7,856 ranibizumab) injections. IOI was detected after a mean of 7 injections (2-12 injections). All eyes had both anterior chamber reaction (Tyndall +1/+3) and vitritis (grade 1-3). None of the patients had pain, hypopyon, or fibrin reaction. Visual acuity progressed to baseline levels within 28.3 days. Vitritis continued with a mean of 40 days. All patients recovered with topical steroid therapy. In 11 eyes, injection of the same anti-VEGF agent was continued. No recurrence of IOI was observed in any patients. Non-infectious IOI following intravitreal anti-VEGF injection typically occurs without pain, conjunctival injection, hypopyon, or fibrin and responds well to topical steroid therapy. Visual acuity returns to baseline levels within weeks according to the severity of inflammation.

20 January 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
FAFerdane Ataş
Ferdane Ataş
MKMahmut Kaya
Mahmut Kaya
ZAZiya Ayhan
Ziya Ayhan
OOOzlem Ozkan
Ozlem Ozkan
MBMerih Birlik
Merih Birlik

1 December 2022 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
FAFerdane Ataş
Ferdane Ataş
MKMahmut Kaya
Mahmut Kaya
ASAli Osman Saatci
Ali Osman Saatci
Objectives: To evaluate the frequency and treatment response of eyes with bacillary layer detachment (BLD) in acute Vogt-KoyanagiHarada (VKH) disease using spectral-domain optical coherence tomography (SD-OCT). Materials and Methods: We retrospectively reviewed the medical records of 58 eyes of acute VKH patients with at least 6 months of follow-up between January 2009 and March 2021. SD-OCT, color fundus photographs, and fluorescein angiography images were analyzed in all patients. Results: The study included 58 eyes of 29 patients. BLD was detected in 33 of the 58 eyes (56.9%) at baseline. Mean serous retinal detachment (SRD) height was 918.50 +/- 336.64 mu m in the BLD group and 215.33 +/- 167.83 mu m in the group without BLD (p<0.05). A positive correlation was found between SRD height and the presence of BLD (r=0.783, p<0.05). BLD was significantly more common in patients with a baseline SRD height greater than 500 mu m (p<0.05). As subfoveal central choroidal thickness (CCT) could not be measured by enhanced depth imaging-OCT at baseline due to extreme choroidal thickness in all eyes, the earliest post-treatment CCT measurements were analyzed. At the completion of pulse steroid therapy, mean CCT was 425 +/- 82.87 mu m in the BLD group and 385.58 +/- 82.87 mu m in the group without BLD (p=0.04). The mean time to BLD resolution was 12.88 +/- 6.5 days (range: 2-26). Conclusion: BLD is a common tomographic finding in eyes with acute VKH disease and can be differentiated from the associated SRD through careful SD-OCT analysis. Though it is mostly observed in patients with more serious disease, the presence of BLD has no negative effect on long-term visual function.

1 November 2022 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
FAFerdane Ataş
Ferdane Ataş
MKMustafa Kayabaşı
Mustafa Kayabaşı
ASAli Osman Saatci
Ali Osman Saatci